Sanctuary Advisors LLC acquired a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 33,429 shares of the company’s stock, valued at approximately $75,000.
Several other institutional investors and hedge funds also recently bought and sold shares of XERS. Vanguard Group Inc. increased its position in Xeris Biopharma by 7.3% in the 1st quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock worth $16,810,000 after purchasing an additional 519,897 shares during the last quarter. Rosalind Advisors Inc. raised its position in Xeris Biopharma by 10.6% during the second quarter. Rosalind Advisors Inc. now owns 3,120,170 shares of the company’s stock valued at $7,020,000 after acquiring an additional 300,000 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Xeris Biopharma by 33.9% in the second quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock valued at $3,041,000 after acquiring an additional 342,300 shares during the last quarter. AQR Capital Management LLC grew its position in Xeris Biopharma by 4.6% in the second quarter. AQR Capital Management LLC now owns 1,193,080 shares of the company’s stock worth $2,684,000 after acquiring an additional 52,074 shares in the last quarter. Finally, Invenomic Capital Management LP increased its stake in shares of Xeris Biopharma by 6.3% during the 1st quarter. Invenomic Capital Management LP now owns 604,512 shares of the company’s stock worth $1,336,000 after purchasing an additional 35,893 shares during the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.
Xeris Biopharma Trading Down 1.0 %
NASDAQ XERS opened at $3.03 on Tuesday. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.46 and a 1-year high of $3.26. The stock’s 50 day moving average is $2.81 and its two-hundred day moving average is $2.36. The company has a market capitalization of $449.22 million, a price-to-earnings ratio of -6.47 and a beta of 2.76.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Xeris Biopharma in a research note on Thursday, August 15th.
View Our Latest Stock Report on Xeris Biopharma
Xeris Biopharma Profile
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Read More
- Five stocks we like better than Xeris Biopharma
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- The How and Why of Investing in Gold Stocks
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Want to see what other hedge funds are holding XERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report).
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.